| PTC |
Report |
CC ARR ex-divested (Q3 FY26) |
IN-LINE |
pred ~$2,445M vs. cons $2,436M |
MEDIUM |
| PTC |
Report |
Net New ARR (Q3 FY26) |
BEAT |
pred ~$52M vs. cons $47.9M |
MEDIUM |
| PTC |
Report |
Non-GAAP EPS (Q3 FY26) |
BEAT |
pred ~$1.75 vs. cons $1.54 |
HIGH |
| PTC |
Guide |
CC ARR growth (FY26) |
UNCHANGED |
guide 7.5-9.5% maintained vs. cons $2,519M |
HIGH |
| PTC |
Guide |
Non-GAAP EPS (FY26) |
BETTER |
guide ~$6.90-$9.10 vs. cons $7.95 |
MEDIUM |
| PTC |
Guide |
FCF (FY26) |
UNCHANGED |
guide ~$850M maintained vs. cons $852M |
HIGH |
| PTC |
Return |
Day-1 residual (stock − beta × S&P 500) |
-1.5% |
— |
MEDIUM |
| PTC |
Return |
5-day cumulative residual |
-3.5% (FADE) |
FADE — FY26 ARR guide unchanged suppresses estimate revisions; pre-print +13.5% run unwinds; EPS beat likely duration-driven (non-recurring), same dynamic as May 6 quarter which faded -7.2% over 5 days |
MEDIUM |